AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 14,281 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 14,281 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $638,503.51. Following the sale, the chief executive officer directly owned 479,344 shares of the company’s stock, valued at $21,431,470.24. This represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Faga also recently made the following trade(s):

• On Wednesday, January 7th, Daniel Faga sold 9,202 shares of AnaptysBio stock. The shares were sold at an average price of $45.11, for a total value of $415,102.22.
• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Price Performance

Shares of AnaptysBio stock traded up $0.87 during trading on Friday, reaching $44.67. 591,811 shares of the company traded hands, compared to its average volume of 739,267. The firm has a market capitalization of $1.24 billion, a PE ratio of -15.84 and a beta of 0.32. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $52.47. The company has a 50 day moving average price of $42.62 and a 200-day moving average price of $31.46.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. Equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded ANAB to a “strong‑buy” and raised its price target to $70, increasing visible upside and likely attracting retail and institutional flows. UBS upgrade / coverage note
• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro’s anticipatory‑breach claim in its Delaware Chancery Court dispute with GSK/Tesaro over Jemperli royalties; a favorable court outcome would lower potential royalty liabilities and legal uncertainty around future cash flows. Reuters: partial dismissal filing
• Positive Sentiment: Company has an active $100M buyback authorization (announced November), which supports shares by reducing float and signals board confidence in valuation.
• Neutral Sentiment: Several institutional investors have recently increased positions substantially (Assenagon, Woodline, 683 Capital, Arrowstreet), which can support liquidity but may not move price immediately.
• Negative Sentiment: Significant insider selling disclosed this week: CEO Daniel Faga sold ~9,202 shares (~$662k) and CFO Dennis Mulroy sold 1,908 shares (and has sold other blocks recently); additional insider dispositions by other executives were also filed — these sales can create near‑term selling pressure or raise questions about insider timing despite large remaining holdings. CEO sale article CFO Form 4
• Negative Sentiment: Clustered insider sales (multiple executives and directors) increase the visible supply and may blunt momentum from upgrades or legal progress until filings show stabilization. SEC Form 4 filings (insider sales)

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC boosted its stake in AnaptysBio by 153.3% during the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 18,165 shares during the period. Woodline Partners LP grew its holdings in shares of AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. Rhumbline Advisers increased its position in shares of AnaptysBio by 2.7% in the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after purchasing an additional 826 shares during the last quarter. Voya Investment Management LLC purchased a new stake in AnaptysBio in the first quarter valued at approximately $1,803,000. Finally, HighMark Wealth Management LLC lifted its position in AnaptysBio by 58.2% during the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after purchasing an additional 53,550 shares during the last quarter.

Analyst Upgrades and Downgrades

ANAB has been the topic of a number of recent research reports. UBS Group started coverage on AnaptysBio in a research report on Wednesday. They set a “buy” rating and a $70.00 price target on the stock. Barclays dropped their price objective on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. HC Wainwright dropped their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Monday, November 24th. Finally, Wedbush reiterated an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.40.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.